Literature DB >> 1793058

Comparison of antiinflammatory and antiallergic drugs in the melittin- and D49 PLA2-induced mouse paw edema models.

D A Hartman1, L A Tomchek, J R Lugay, A C Lewin, T T Chau, R P Carlson.   

Abstract

Melittin (MLT) (10 micrograms/paw) and D49 (0.4 micrograms/paw) were injected into the hind paw of male CD-1 mice and elicited 70-80% of maximal paw edema responses at 60 and 30 min after injection, respectively. D49 paw edema was significantly inhibited by anti-histamine/serotonin agents, a PAF antagonist, a PLA2 inhibitor, and some but not all 5-LO and CO inhibitors, indicating that this edema is produced by several classes of inflammatory mediators with mast cell degranulation apparently playing a major role. In contrast, MLT paw edema was not inhibited effectively using the same pharmacological agents except theophylline, suggesting it was elicited via a different sequence of inflammatory events. In summary, D49 and MLT paw edema models were found to be ineffective models to identify experimental PLA2 compounds in our laboratory.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1793058     DOI: 10.1007/bf01993245

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  5 in total

1.  Pharmacologic modulation of D-49 phospholipase A2-induced paw edema in the mouse.

Authors:  W Calhoun; J Yu; A Sung; T T Chau; L A Marshall; B M Weichman; R P Carlson
Journal:  Agents Actions       Date:  1989-06

2.  A study of phospholipase A2-induced oedema in rat paw.

Authors:  G Cirino; S H Peers; J L Wallace; R J Flower
Journal:  Eur J Pharmacol       Date:  1989-08-03       Impact factor: 4.432

3.  A phospholipase A2-activating protein (PLAP) stimulates human neutrophil aggregation and release of lysosomal enzymes, superoxide, and eicosanoids.

Authors:  J S Bomalaski; D G Baker; L Brophy; N V Resurreccion; I Spilberg; M Muniain; M A Clark
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

4.  Stimulation of lipoxygenase product synthesis in human leukocytes and platelets by melittin.

Authors:  H Salari; P Braquet; P Borgeat
Journal:  Mol Pharmacol       Date:  1985-12       Impact factor: 4.436

5.  Pharmacological study of phospholipase A2-induced histamine release from rat peritoneal mast cells.

Authors:  S H Choi; T Sakamoto; O Fukutomi; N Inagaki; N Matsuura; H Nagai; A Koda
Journal:  J Pharmacobiodyn       Date:  1989-09
  5 in total
  4 in total

Review 1.  The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword.

Authors:  Jun Chen; William R Lariviere
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

2.  Bee Venom Induces Acute Inflammation through a H2O2-Mediated System That Utilizes Superoxide Dismutase.

Authors:  Kwang-Sik Lee; Bo-Yeon Kim; Min-Ji Park; Yijie Deng; Jin-Myung Kim; Yun-Hui Kim; Eun-Jee Heo; Hyung-Joo Yoon; Kyeong-Yong Lee; Yong-Soo Choi; Byung-Rae Jin
Journal:  Toxins (Basel)       Date:  2022-08-17       Impact factor: 5.075

3.  Serum sickness reaction with skin involvement induced by bee venom injection therapy.

Authors:  Hyun-Jung Seo; Junehyuk Lee
Journal:  Asia Pac Allergy       Date:  2015-10-28

4.  In Vitro and In Vivo Anti-Allergic and Anti-Inflammatory Effects of eBV, a Newly Developed Derivative of Bee Venom, through Modulation of IRF3 Signaling Pathway in a Carrageenan-Induced Edema Model.

Authors:  Hwa-Jin Chung; Jinho Lee; Joon-Shik Shin; Me-Riong Kim; Wonil Koh; Min-Jeong Kim; Jae-Woong Lee; Eun Jee Kim; In-Hee Lee; Won Kyung Kim; Yoon Jae Lee; Sang Kook Lee; In-Hyuk Ha
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.